StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD – Free Report) in a research report report published on Sunday. The brokerage issued a sell rating on the medical equipment provider’s stock.
Separately, HC Wainwright lowered their price target on shares of Aethlon Medical from $23.00 to $10.00 and set a buy rating for the company in a research report on Monday, March 4th.
Check Out Our Latest Report on Aethlon Medical
Aethlon Medical Stock Performance
Aethlon Medical (NASDAQ:AEMD – Get Free Report) last released its quarterly earnings results on Wednesday, February 14th. The medical equipment provider reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.14). Sell-side analysts expect that Aethlon Medical will post -4.98 EPS for the current fiscal year.
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
See Also
- Five stocks we like better than Aethlon Medical
- Conference Calls and Individual Investors
- AMD is Down 35%. Now is the Time to Buy the Dip
- Are Penny Stocks a Good Fit for Your Portfolio?
- Amazon Stands Tall: New Highs Are in Sight
- 10 Best Airline Stocks to Buy
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.